FY2026 Earnings Estimate for Savara Issued By HC Wainwright

Savara Inc. (NASDAQ:SVRA) – Analysts at HC Wainwright decreased their FY2026 EPS estimates for shares of Savara in a report issued on Monday, March 16th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.49) per share for the year, down from their previous forecast of ($0.39). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara’s FY2027 earnings at ($0.28) EPS and FY2028 earnings at $0.02 EPS.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Friday, March 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

A number of other research firms have also recently commented on SVRA. William Blair set a $10.00 target price on Savara in a research report on Monday. Wells Fargo & Company upped their price target on Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, December 18th. UBS Group set a $10.00 price target on Savara in a research report on Tuesday, December 23rd. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Savara Trading Up 2.4%

Shares of Savara stock opened at $5.16 on Wednesday. The firm has a 50-day simple moving average of $5.62 and a two-hundred day simple moving average of $5.00. The company has a market cap of $1.06 billion, a P/E ratio of -9.74 and a beta of 0.31. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $7.01. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.65 and a current ratio of 11.85.

Institutional Investors Weigh In On Savara

Large investors have recently modified their holdings of the business. Osaic Holdings Inc. raised its position in shares of Savara by 6.9% in the fourth quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock valued at $197,000 after buying an additional 2,098 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Savara by 3.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock worth $420,000 after acquiring an additional 2,116 shares during the last quarter. Graham Capital Management L.P. boosted its position in Savara by 4.9% during the fourth quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock worth $338,000 after acquiring an additional 2,615 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Savara by 9.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock valued at $200,000 after acquiring an additional 2,859 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Savara by 48.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after acquiring an additional 3,205 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.